Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function
Избирательная мишень: инозинмонофосфатдегидрогеназа-2 снижает метастатический потенциал в мозг при сохранении функции иммунных клеток
2026-06-17
SCID: 54.1/xkpsmtep
Discuss with AI
IMPDH2IMPDH2-selective inhibitorsOsimertinib synergybrain metastasisbrain metastasis-initiating cells
Figures from the paper
Abstract (AI)
Brain metastases (BM) occur in 26% of cancer patients and have a 90% mortality rate within 1 y of diagnosis, yet the current standard of care remains palliative. We have previously shown that de novo GTP synthesis is a druggable metabolic vulnerability in BM cells, through its rate-limiting enzyme, inosine monophosphate dehydrogenase (IMPDH). IMPDH inhibitors have progressed to phase-II oncology trials in the past, failing largely due to dose-limiting toxicities associated with off-target inhibition of IMPDH1, the constitutively expressed isoenzyme in normal human lymphocytes. Here, we determined that a single subtype (isoenzyme) of IMPDH, IMPDH2, is specifically upregulated in brain metastasis-initiating cells (BMICs), absent in normal brain tissue, and is sufficient to drive the formation of BM. Moreover, we show that genetic knockout of IMPDH2 stops the proliferation of BM cells in vitro and the onset of BM in vivo. We synthesized IMPDH2-selective compounds and showed that they maintain a potent antiproliferation effect on BMICs, but spare immune cell function compared to previously developed pan-IMPDH inhibitors. Furthermore, we introduce a positive correlation between compound selectivity for IMPDH2 and the ability to synergize with Osimertinib: the standard of care for EGFR-mutant non-small cell lung cancer. Overall, our results suggest that specifically blocking IMPDH2 is an effective therapeutic strategy for BM by overcoming the immune suppressive effects that have hindered the clinical development of pan-IMPDH inhibitors in the past. An IMPDH2 specific therapy could be coadministered with primary tumor standard of care treatments to provide a safe and interceptional approach for BM.
Key Findings
1
Greater selectivity for IMPDH2 correlates with improved synergy with Osimertinib, the standard of care for EGFR-mutant non-small cell lung cancer
2
IMPDH2 is specifically upregulated in brain metastasis-initiating cells (BMICs) and absent in normal brain tissue
3
IMPDH2 is sufficient to drive brain metastasis formation, and genetic knockout of IMPDH2 halts BM cell proliferation in vitro and BM onset in vivo
4
IMPDH2-selective compounds potently inhibit BMIC proliferation while preserving immune cell function compared to pan-IMPDH inhibitors
5
Targeting IMPDH2 specifically could overcome immune-suppressive toxicities of pan-IMPDH inhibitors and enable safe coadministration with primary tumor therapies for BM interception
Research Object
Inosine monophosphate dehydrogenase 2 (IMPDH2) in brain metastasis-initiating cells and brain metastases
Research Subject
The effects of selective targeting/inhibition or genetic knockout of IMPDH2 on BM cell proliferation and brain metastasis formation, immune cell function sparing compared to pan-IMPDH inhibition, and synergy with Osimertinib
Publication Details
Publication Date
2026-06-17
Journal
Publisher
ISSN
Cited by
0
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest